PD-1 Inhibitor Market
Jun 14, 2024
OPDIVO vs. KEYTRUDA: The Battle for Japan’s PD-1 Inhibitor Market Dominance
Bristol Myers Squibb’s PD-1 inhibitor, OPDIVO, has deep roots in Japan. In July 2014, MHLW approved OPDIVO to treat melanoma, marking it the first approved PD-1 inhibitor globally. About two years later, KEYTRUDA gained approval in Japan for the same indications (melanoma and NSCLC). This set the stage for fierce c...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
